John C. Byrd
Division of Hematology
Department of Internal Medicine
Ohio State University
Columbus
USA
Name/email consistency: high
- Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. Byrd, J.C., Furman, R.R., Coutre, S.E., Flinn, I.W., Burger, J.A., Blum, K.A., Grant, B., Sharman, J.P., Coleman, M., Wierda, W.G., Jones, J.A., Zhao, W., Heerema, N.A., Johnson, A.J., Sukbuntherng, J., Chang, B.Y., Clow, F., Hedrick, E., Buggy, J.J., James, D.F., O'Brien, S. N. Engl. J. Med. (2013)
- Quantitative DNA Methylation Analysis Identifies a Single CpG Dinucleotide Important for ZAP-70 Expression and Predictive of Prognosis in Chronic Lymphocytic Leukemia. Claus, R., Lucas, D.M., Stilgenbauer, S., Ruppert, A.S., Yu, L., Zucknick, M., Mertens, D., Bühler, A., Oakes, C.C., Larson, R.A., Kay, N.E., Jelinek, D.F., Kipps, T.J., Rassenti, L.Z., Gribben, J.G., Döhner, H., Heerema, N.A., Marcucci, G., Plass, C., Byrd, J.C. J. Clin. Oncol. (2012)
- Flavopiridol treatment of patients aged 70 or older with refractory or relapsed chronic lymphocytic leukemia is a feasible and active therapeutic approach. Stephens, D.M., Ruppert, A.S., Blum, K., Jones, J., Flynn, J.M., Johnson, A.J., Ji, J., Phelps, M.A., Grever, M.R., Byrd, J.C. Haematologica (2012)
- Phase 1/2 study of lumiliximab combined with fludarabine, cyclophosphamide, and rituximab in patients with relapsed or refractory chronic lymphocytic leukemia. Byrd, J.C., Kipps, T.J., Flinn, I.W., Castro, J., Lin, T.S., Wierda, W., Heerema, N., Woodworth, J., Hughes, S., Tangri, S., Harris, S., Wynne, D., Molina, A., Leigh, B., O'Brien, S. Blood (2010)
- Fludarabine followed by alemtuzumab consolidation for previously untreated chronic lymphocytic leukemia: final report of Cancer and Leukemia Group B study 19901. Byrd, J.C., Peterson, B.L., Rai, K.R., Hurd, D., Hohl, R., Perry, M.C., Gockerman, J., Nattam, S., Larson, R.A. Leuk. Lymphoma (2009)
- Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia. Byrd, J.C., Lin, T.S., Dalton, J.T., Wu, D., Phelps, M.A., Fischer, B., Moran, M., Blum, K.A., Rovin, B., Brooker-McEldowney, M., Broering, S., Schaaf, L.J., Johnson, A.J., Lucas, D.M., Heerema, N.A., Lozanski, G., Young, D.C., Suarez, J.R., Colevas, A.D., Grever, M.R. Blood (2007)
- Phase 1 study of lumiliximab with detailed pharmacokinetic and pharmacodynamic measurements in patients with relapsed or refractory chronic lymphocytic leukemia. Byrd, J.C., O'Brien, S., Flinn, I.W., Kipps, T.J., Weiss, M., Rai, K., Lin, T.S., Woodworth, J., Wynne, D., Reid, J., Molina, A., Leigh, B., Harris, S. Clin. Cancer Res. (2007)
- Select high-risk genetic features predict earlier progression following chemoimmunotherapy with fludarabine and rituximab in chronic lymphocytic leukemia: justification for risk-adapted therapy. Byrd, J.C., Gribben, J.G., Peterson, B.L., Grever, M.R., Lozanski, G., Lucas, D.M., Lampson, B., Larson, R.A., Caligiuri, M.A., Heerema, N.A. J. Clin. Oncol. (2006)
